Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics logo
$69.22 -3.72 (-5.10%)
Closing price 04:00 PM Eastern
Extended Trading
$68.95 -0.27 (-0.39%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CORT vs. ANVS, ZTS, VTRS, NBIX, and JAZZ

Should you buy Corcept Therapeutics stock or one of its competitors? Corcept Therapeutics's main competitors and comparable companies include Annovis Bio (ANVS), Zoetis (ZTS), Viatris (VTRS), Neurocrine Biosciences (NBIX), and Jazz Pharmaceuticals (JAZZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Corcept Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Annovis Bio had 3 more articles in the media than Corcept Therapeutics. MarketBeat recorded 7 mentions for Annovis Bio and 4 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.60 beat Annovis Bio's score of 0.44 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annovis Bio
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 15.9% of Annovis Bio shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.79N/A
Corcept Therapeutics$761.41M10.48$99.65M$1.2757.43

Corcept Therapeutics has a net margin of 16.53% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 22.56% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -986.96% -261.39%
Corcept Therapeutics 16.53%22.56%17.83%

Annovis Bio has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Annovis Bio presently has a consensus target price of $12.00, indicating a potential upside of 1,197.30%. Corcept Therapeutics has a consensus target price of $139.50, indicating a potential upside of 91.25%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Corcept Therapeutics beats Annovis Bio on 12 of the 15 factors compared between the two stocks.

How does Corcept Therapeutics compare to Zoetis?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Zoetis had 6 more articles in the media than Corcept Therapeutics. MarketBeat recorded 10 mentions for Zoetis and 4 mentions for Corcept Therapeutics. Zoetis' average media sentiment score of 0.61 beat Corcept Therapeutics' score of 0.60 indicating that Zoetis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoetis
6 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$9.49B3.58$2.67B$5.8814.23
Corcept Therapeutics$761.41M10.48$99.65M$1.2757.43

Zoetis has a net margin of 26.15% compared to Corcept Therapeutics' net margin of 16.53%. Zoetis' return on equity of 85.90% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zoetis26.15% 85.90% 18.39%
Corcept Therapeutics 16.53%22.56%17.83%

92.8% of Zoetis shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zoetis has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Zoetis presently has a consensus price target of $101.25, suggesting a potential upside of 21.04%. Corcept Therapeutics has a consensus price target of $139.50, suggesting a potential upside of 91.25%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Zoetis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis
1 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.33
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Zoetis beats Corcept Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

79.9% of Viatris shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Viatris currently has a consensus target price of $21.11, suggesting a potential upside of 1.40%. Corcept Therapeutics has a consensus target price of $139.50, suggesting a potential upside of 91.25%. Given Corcept Therapeutics' higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatris
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, Viatris and Viatris both had 4 articles in the media. Viatris' average media sentiment score of 0.84 beat Corcept Therapeutics' score of 0.60 indicating that Viatris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viatris
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Corcept Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viatris$14.73B1.62-$3.51B-$0.53N/A
Corcept Therapeutics$761.41M10.48$99.65M$1.2757.43

Corcept Therapeutics has a net margin of 16.53% compared to Viatris' net margin of -4.13%. Corcept Therapeutics' return on equity of 22.56% beat Viatris' return on equity.

Company Net Margins Return on Equity Return on Assets
Viatris-4.13% 20.82% 8.30%
Corcept Therapeutics 16.53%22.56%17.83%

Summary

Corcept Therapeutics beats Viatris on 10 of the 15 factors compared between the two stocks.

How does Corcept Therapeutics compare to Neurocrine Biosciences?

Corcept Therapeutics (NASDAQ:CORT) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Neurocrine Biosciences has a net margin of 18.98% compared to Corcept Therapeutics' net margin of 16.53%. Neurocrine Biosciences' return on equity of 23.39% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics16.53% 22.56% 17.83%
Neurocrine Biosciences 18.98%23.39%16.22%

Corcept Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Corcept Therapeutics. MarketBeat recorded 10 mentions for Neurocrine Biosciences and 4 mentions for Corcept Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.04 beat Corcept Therapeutics' score of 0.60 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Corcept Therapeutics presently has a consensus price target of $139.50, indicating a potential upside of 91.25%. Neurocrine Biosciences has a consensus price target of $202.59, indicating a potential upside of 21.02%. Given Corcept Therapeutics' higher possible upside, equities research analysts plainly believe Corcept Therapeutics is more favorable than Neurocrine Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Neurocrine Biosciences
0 Sell rating(s)
4 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.88

Neurocrine Biosciences has higher revenue and earnings than Corcept Therapeutics. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M10.48$99.65M$1.2757.43
Neurocrine Biosciences$2.86B5.92$478.60M$6.7424.84

Summary

Neurocrine Biosciences beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jazz Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, Jazz Pharmaceuticals had 9 more articles in the media than Corcept Therapeutics. MarketBeat recorded 13 mentions for Jazz Pharmaceuticals and 4 mentions for Corcept Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.92 beat Corcept Therapeutics' score of 0.60 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jazz Pharmaceuticals currently has a consensus price target of $294.25, suggesting a potential upside of 21.82%. Corcept Therapeutics has a consensus price target of $139.50, suggesting a potential upside of 91.25%. Given Corcept Therapeutics' higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.95
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Corcept Therapeutics has a net margin of 16.53% compared to Jazz Pharmaceuticals' net margin of 4.37%. Corcept Therapeutics' return on equity of 22.56% beat Jazz Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals4.37% 16.88% 6.46%
Corcept Therapeutics 16.53%22.56%17.83%

Corcept Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Corcept Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.27B3.63-$356.15M$2.9482.16
Corcept Therapeutics$761.41M10.48$99.65M$1.2757.43

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CORT vs. The Competition

MetricCorcept TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.07B$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E Ratio58.0426.0432.9127.39
Price / Sales9.957.318.595.74
Price / Cash81.6515.7421.9322.50
Price / Book9.085.144.403.70
Net Income$99.65M$2.88B$3.52B$392.17M
7 Day Performance-7.74%-3.87%-5.34%-4.53%
1 Month Performance-37.16%-3.96%-3.61%-5.86%
1 Year Performance-8.37%-7.13%0.01%-7.78%

Corcept Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CORT
Corcept Therapeutics
4.0396 of 5 stars
$69.22
-5.1%
$139.50
+101.5%
-3.4%$8.07B$761.41M58.04730
ANVS
Annovis Bio
3.6753 of 5 stars
$1.20
+9.6%
$12.00
+904.2%
-61.1%$46.52MN/AN/A7
ZTS
Zoetis
4.6403 of 5 stars
$88.60
+6.8%
$93.79
+5.9%
-30.7%$34.29B$9.47B14.6014,500
VTRS
Viatris
2.3991 of 5 stars
$19.22
+1.6%
$20.88
+8.6%
+94.2%$21.73B$14.30BN/A30,000
NBIX
Neurocrine Biosciences
4.9324 of 5 stars
$166.05
+0.7%
$202.32
+21.8%
+15.6%$16.69B$2.86B24.642,000

Related Companies and Tools


This page (NASDAQ:CORT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners